De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials
ConclusionAmong patients with ACS treated with PCI, a de-escalation strategy (prasugrel or ticagrelor to clopidogrel) is associated with lower ischemic and bleeding events (net clinical benefits) and lower BARC type 2 or higher bleeding; however, due to the limited number of included studies, further high-quality studies are needed to establish the clinical efficacy of the de-escalation strategy.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Academia | Angioplasty | Aspirin | Bleeding | Cardiology | Cardiovascular | Clinical Trials | Clopidogrel | Coronary Angioplasty | Databases & Libraries | Heart | Percutaneous Coronary Intervention | Plavix | Science | Study